Allergan Financial Statements (AGN)
|
|
|
|
Report date
|
|
|
26.02.2016 |
24.02.2017 |
16.02.2018 |
15.02.2019 |
18.02.2020 |
|
07.05.2020 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
12 688 |
14 571 |
15 941 |
15 787 |
16 089 |
|
16 096 |
|
Operating Income, bln rub |
|
|
-3 131 |
-1 826 |
-5 975 |
-6 049 |
-4 446 |
|
-3 436 |
|
EBITDA, bln rub |
? |
|
9 542 |
21 003 |
-2 332 |
792.7 |
1 719 |
|
2 716 |
|
Net profit, bln rub |
? |
|
3 915 |
14 973 |
-4 126 |
-5 096 |
-5 271 |
|
-2 485 |
|
|
OCF, bln rub |
? |
|
4 606 |
1 446 |
6 079 |
5 640 |
7 239 |
|
6 121 |
|
CAPEX, bln rub |
? |
|
454.9 |
331.4 |
349.9 |
253.5 |
375.0 |
|
370.9 |
|
FCF, bln rub |
? |
|
4 151 |
1 114 |
5 729 |
5 387 |
6 864 |
|
5 750 |
|
Dividend payout, bln rub
|
|
|
208.1 |
278.4 |
1 218 |
1 050 |
974.4 |
|
971.8 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
5.32% |
1.86% |
0.00% |
0.00% |
0.00% |
|
-39.1% |
|
|
OPEX, bln rub |
|
|
13 067 |
14 535 |
19 748 |
19 645 |
18 099 |
|
16 947 |
|
Cost of production, bln rub |
|
|
2 752 |
1 861 |
2 168 |
2 191 |
2 435 |
|
2 584 |
|
R&D, bln rub |
|
|
2 359 |
2 576 |
2 100 |
2 266 |
1 812 |
|
1 807 |
|
Interest expenses, bln rub |
|
|
1 193 |
1 296 |
1 096 |
911.2 |
783.0 |
|
765.8 |
|
|
Assets, bln rub |
|
|
135 583 |
128 986 |
118 342 |
101 788 |
94 699 |
|
88 426 |
|
Net Assets, bln rub |
? |
|
76 591 |
76 193 |
73 821 |
65 114 |
58 174 |
|
57 998 |
|
Debt, bln rub |
|
|
42 530 |
32 769 |
30 075 |
23 798 |
22 649 |
|
19 550 |
|
Cash, bln rub |
|
|
1 105 |
13 226 |
6 449 |
1 907 |
5 915 |
|
2 618 |
|
Net debt, bln rub |
|
|
41 425 |
19 543 |
23 626 |
21 890 |
16 734 |
|
16 931 |
|
|
Ordinary share price, rub |
|
|
312.5 |
210.0 |
163.6 |
133.7 |
191.2 |
|
193.0 |
|
Number of ordinary shares, mln |
|
|
367.8 |
384.9 |
333.8 |
337.0 |
329.0 |
|
331.9 |
|
|
Market cap, bln rub |
|
|
114 938 |
80 833 |
54 603 |
45 043 |
62 895 |
|
64 070 |
|
EV, bln rub |
? |
|
156 363 |
100 376 |
78 229 |
66 934 |
79 629 |
|
81 001 |
|
Book value, bln rub |
|
|
-37 710 |
-32 782 |
-30 690 |
-24 495 |
-21 965 |
|
-19 498 |
|
|
EPS, rub |
? |
|
10.6 |
38.9 |
-12.4 |
-15.1 |
-16.0 |
|
-7.49 |
|
FCF/share, rub |
|
|
11.3 |
2.90 |
17.2 |
16.0 |
20.9 |
|
17.3 |
|
BV/share, rub |
|
|
-102.5 |
-85.2 |
-91.9 |
-72.7 |
-66.8 |
|
-58.7 |
|
|
EBITDA margin, % |
? |
|
75.2% |
144.1% |
-14.6% |
5.02% |
10.7% |
|
16.9% |
|
Net margin, % |
? |
|
30.9% |
102.8% |
-25.9% |
-32.3% |
-32.8% |
|
-15.4% |
|
FCF yield, % |
? |
|
3.61% |
1.38% |
10.5% |
12.0% |
10.9% |
|
8.98% |
|
ROE, % |
? |
|
5.11% |
19.7% |
-5.59% |
-7.83% |
-9.06% |
|
-4.28% |
|
ROA, % |
? |
|
2.89% |
11.6% |
-3.49% |
-5.01% |
-5.57% |
|
-2.81% |
|
|
P/E |
? |
|
29.4 |
5.40 |
-13.2 |
-8.84 |
-11.9 |
|
-25.8 |
|
P/FCF |
|
|
27.7 |
72.5 |
9.53 |
8.36 |
9.16 |
|
11.1 |
|
P/S |
? |
|
9.06 |
5.55 |
3.43 |
2.85 |
3.91 |
|
3.98 |
|
P/BV |
? |
|
-3.05 |
-2.47 |
-1.78 |
-1.84 |
-2.86 |
|
-3.29 |
|
EV/EBITDA |
? |
|
16.4 |
4.78 |
-33.6 |
84.4 |
46.3 |
|
29.8 |
|
Debt/EBITDA |
|
|
4.34 |
0.93 |
-10.1 |
27.6 |
9.73 |
|
6.23 |
|
|
R&D/CAPEX, % |
|
|
518.5% |
777.2% |
600.2% |
894.0% |
483.2% |
|
487.2% |
|
|
CAPEX/Revenue, % |
|
|
3.59% |
2.27% |
2.20% |
1.61% |
2.33% |
|
2.30% |
|
| Allergan shareholders |
